De
Da
En
Fr
Sv
Deal History
Services
Corporate Finance
Debt Advisory
Aktienanalyse
Growth Equity
IPO Strategie und Vorbereitung
Industries
Business Services
Consumer & Internet
Industrial Technology
Life Science
Software & TMT
Energy & Infrastructure
Insights
News
Newsletter
Research
Über Uns
Die Firma
Team
Büros
Globalscope
Karriere
Events
Kontakt
De
Da
En
Fr
Sv
Main menu button
We support Ukraine
Team
Deals
Kontakt
We support Ukraine
Team
Deals
Kontakt
News
Alle
Abera Bioscience
Adventure Box
Adverty
All for One Group
ALM Equity
Alzecure Pharma
Arctic Minerals
Biosergen
Candles Scandinavia
Carlsquare
CellaVision
CSAM Health Group
DanCann Pharma
Ecoclime
Elicera Therapeutics
Frequentis
FRISQ
Future Gaming
GHP Specialty Care
H&D Wireless
Hanza
Herantis Pharma
InCoax
Kancera
Medclair Invest
Midsummer
Modus Therapeutics
Moninvent
NeoDynamics
Nischer Properties
Nosa Plugs
Observit
Orion Corporation
Pharmiva
Raytelligence
Risk Intelligence
SBB i Norden
Sensec
Spotlight Group
Svenska Aerogel
Svenska Aerogel
Thinc Jetty
Ytrade Group
Zazz Energy
Zinzino
Alle
Corporate Finance
Equity Research
Events
Events
M&A Know-how
Macro
Market Snapshots
Media
Pressemeldungen
Unkategorisiert
16 Aug 2023
Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline
Equity Research
Biosergen
29 Mrz 2023
Equity research Biosergen: Plans for speedy development of lead candidate
Equity Research
Biosergen
20 Mrz 2023
Initiation of coverage, Biosergen: Make antifungals great again
Equity Research
Biosergen
